logo090625_
cropped_Image_d7zp7ad7zp7ad7zp

WELCOME TO

NANOLUMINA

NanoLumina Technologies pioneers light-activated nanomedicine platforms
for precision cancer therapy. Our hybrid nanoparticles combine
photothermal, photoimmunological, and image-guided capabilities to tackle solid tumors with exceptional specificity and minimal invasiveness. 

Founded by leading scientists in biomedical nanotechnology, we aim to
revolutionize cancer treatment through intelligent, light-triggered
therapeutics, bridging the gap between materials innovation and clinical
application 

Translating Innovation Into

LIGHT-DRIVEN
CANCER THERAPIES

cropped_Image_r28q8cr28q8cr28q
OUR

UPCOMING EVENTS

NIR-II photothermal agent

Our latest work is published in Small Methods!

More Details
CIHR Pitch
Presentatlon

Pitching NanoLumina's platform for
photoimmunotherapy to CIHR's Health
Innovation Grant Panel. Exploring translational
funding pathways

More Details
Publication in Nature STTT (IF: 52.7)

Our publication is coming up in Nature STTT

More Details
Signature: JCMH7uLO9nEQVQn1Kaq0ywGw1HTIvVZsx5ghijM08RZnJ6XjXrh4EXj7i4HTbRuGKXpw944+vfHfOM/LdnFDNHE74gtjlbmnqr1gbndXkbL5ynTrNa1L6n6Q95Lz4farLGq0j4ZMquCTzFq+ClwS0o85D+SNmbPc33etPTmwmYs=

OUR TECHNOLOGY

INTELLIGENT
NANOMATERIALS

We engineer hybrid nanoplatforms for deep-tissue targeting, light-activated
drug delivery, and immune modulation-empowering next-gen cancer
therapy.

Multifunctional nanomedicines

Our nanoplatforms are engineered with multi-functional layers. This structure enables enhanced targeting specificity, controlled payload release, and integrated imaging—all within a single nanoscale device.

NIR-II Triggered Ablatlon

Utilizing NIR-II (1000–1300 nm) wavelengths, our particles deliver focused energy deep within tissues—activating photothermal ablation, drug release, and immune stimulation in tandem. This allows deeper tissue penetration, higher safety margins, and real-time therapeutic control.

EXPLORE MORE